MORF-057

DRUG4 trials

Sponsors

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Conditions

Colitis, UlcerativeCrohn's DiseaseHealthy VolunteersInflammatory Bowel Diseases

Phase 1

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

CompletedNCT04580745

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Healthy Volunteers

Start: 2020-09-23End: 2021-04-12Updated: 2025-08-01

Phase 2

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

CompletedNCT05291689

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Colitis, Ulcerative, Inflammatory Bowel Diseases

Start: 2022-04-13End: 2025-02-19Updated: 2026-03-11

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Active, not recruitingNCT05611671

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Colitis, Ulcerative, Inflammatory Bowel Diseases

Start: 2022-11-21End: 2026-08-31Updated: 2025-12-15

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

RecruitingNCT06226883

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Crohn's Disease, Inflammatory Bowel Diseases

Start: 2024-07-18End: 2030-06-01Target: 385Updated: 2026-03-20

Related Papers

A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.

2025-08-061 citations

P1002 Changes in circulating lymphocyte subsets and CCR9 transcripts as mechanistic biomarkers of the small molecule α4β7 inhibitor MORF-057 in patients with Ulcerative Colitis

Journal of Crohn s and Colitis2025-01-012 citations

S793 Full Target Engagement With Saturation of α4β7 Integrin Receptor Occupancy Resulting in Changes in Subset of Lymphocytes by MORF-057 Following 200 Mg Daily Dosing in Healthy Subjects

The American Journal of Gastroenterology2022-10-01

P306 MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects

Journal of Crohn s and Colitis2021-05-015 citations